Journal article

Combined BRAF and MEK inhibition in BRAF-mutant NSCLC

Gareth Rivalland, Paul Mitchell

The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2016

DOI: 10.1016/S1470-2045(16)30203-0

University of Melbourne Researchers

Citation metrics

4Web of Science
5Scopus
5Dimensions

Keywords

Science & Technology
Dabrafenib
Carcinoma, Non-Small-Cell Lung
Multicenter
Proto-Oncogene Proteins B-Raf
Cell Lung-Cancer
Humans
Lung Neoplasms
Oncology
Protein Kinase Inhibitors
Melanoma
Life Sciences & Biomedicine
Trametinib
Cell Line, Tumor
Open-Label
Randomized Controlled-Trial
Mutation